LOS ANGELES, Oct. 19, 2015 /PRNewswire/ -- MAX BioPharma, Inc. (www.maxbiopharma.com) announced today that it has successfully demonstrated potent osteogenic activity as well as tissue selectivity of its proprietary small molecule oxysterols that are bone-targeted. The research was conducted as part of MAX BioPharma's two SBIR Phase 1 grants that supported its activities in the area of osteoporosis. The company believes that these novel molecules are ideal candidates for further therapeutic development into bone anabolic agents for the treatment of osteoporosis by targeting specific stem cells in the skeleton that give rise to bone forming cells. In related news, MAX BioPharma recently received excellent reviews from the National Institutes of Health on two Phase 2 SBIR grants that will provide additional resources for the continued development of its osteoporosis program that focuses on novel bone anabolic oxysterols. Furthermore, MAX BioPharma recently licensed from the University of Louisville an intellectual property portfolio that protects a proprietary bone delivery technology based on novel tetracycline analogues that complements MAX BioPharma's core technology. Commenting on this, Allen Morris, PhD, MBA, Director of The University of Louisville's Technology Transfer Office, stated, "We are pleased to have partnered with MAX BioPharma through our technology licensing agreement and we are hopeful that the University of Louisville's bone-targeting innovation will assist the company in executing its strategic plan for commercialization and in bringing promising therapeutics to patients."
The company will be presenting at the 14th Annual BIO Investor Forum to be held in San Francisco, California, October 20-21, 2015 (https://www.bio.org/events/conferences/14th-annual-bio-investor-forum). The company will describe its oxysterol platform and efforts to develop new candidate molecules that have promise for bone growth stimulation and anti-tumorigenic activity.
About MAX BioPharma
MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company that is developing novel small molecule lipids as candidates for therapeutic development into future drugs for debilitating and fatal human diseases. The company will be a leader in a new field of "oxysterol therapeutics" by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerous indications. MAX BioPharma's first success based on small molecule lipids has contributed to the discovery of novel osteogenic oxysterol compounds that target multipotent mesenchymal cells, including mesenchymal stem cells, to induce the formation of bone-forming osteoblasts and bone. The company is translating this technology into the next generation of therapeutic agents for stimulation of bone formation, locally and systemically, in indications such as spinal fusion, non-union fractures, and osteoporosis. MAX BioPharma is also pursuing the development of small molecule oxysterols that function as Hedgehog pathway antagonists that will be more effective than currently known Hedgehog pathway antagonists in treating a variety of Hedgehog pathway-related cancers, including pancreatic cancer and multiple myeloma. For more information please visit us at www.maxbiopharma.com
Safe Harbor: This document contains non-confidential information. No representations or warranty is made as to the completeness of the statements and information contained herein, and nothing contained in this document is, or shall be relied upon as a promise or representation as to the future. All information contained herein should be verified by parties considering any sort of transaction with the Company through their own due diligence process. This document does not constitute an offer to sell or a solicitation of an offer to purchase any securities.
Media Contact: Jason Rifkin
SOURCE MAX BioPharma